These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38430481)

  • 1. Development of cytomegalovirus resistant to maribavir: real world, real problem?
    Kleiboeker HL; Prom A; Paplaczyk K
    Transpl Infect Dis; 2024 Apr; 26(2):e14259. PubMed ID: 38430481
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
    Chou S; Alain S; Cervera C; Chemaly RF; Kotton CN; Lundgren J; Papanicolaou GA; Pereira MR; Wu JJ; Murray RA; Buss NE; Fournier M
    J Infect Dis; 2024 Feb; 229(2):413-421. PubMed ID: 37506264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of maribavir versus conventional antiviral therapies for post-transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective.
    Schultz BG; Kotton CN; Jutlla G; Ressa R; de Lacey T; Chowdhury E; Bo T; Fenu E; Gelone DK; Poirrier JE; Amorosi SL
    J Med Virol; 2024 Apr; 96(4):e29609. PubMed ID: 38647051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Maribavir for Multidrug Resistant Cytomegaloviremia in a Pediatric Oncology Patient.
    Fisher JE; Mulieri K; Finch E; Ericson JE
    J Pediatr Hematol Oncol; 2024 Apr; 46(3):e244-e247. PubMed ID: 38447094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient.
    Pearce H; Montgomery EK; Sheerin N; Ellam H
    Transpl Int; 2024; 37():11985. PubMed ID: 38314399
    [No Abstract]   [Full Text] [Related]  

  • 6. [Not Available].
    Loft JA; Riis PT; Schultz NA; Bjerrum S; Schønning K; Pedersen CR; Krohn PS; Nielsen SD
    Ugeskr Laeger; 2024 Apr; 186(15):. PubMed ID: 38708697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants.
    Chou S; Watanabe J
    Antiviral Res; 2024 Feb; 222():105792. PubMed ID: 38163624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maribavir failure in refractory cytomegalovirus infection in a lung transplant patient on extracorporeal membrane oxygenation.
    Kroll C; Non L; Ince D
    Transpl Infect Dis; 2024 Jun; 26(3):e14275. PubMed ID: 38584587
    [No Abstract]   [Full Text] [Related]  

  • 9. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
    Avery RK; Alain S; Alexander BD; Blumberg EA; Chemaly RF; Cordonnier C; Duarte RF; Florescu DF; Kamar N; Kumar D; Maertens J; Marty FM; Papanicolaou GA; Silveira FP; Witzke O; Wu J; Sundberg AK; Fournier M;
    Clin Infect Dis; 2022 Sep; 75(4):690-701. PubMed ID: 34864943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EFFICACY OF MARIBAVIR IN VALGANCICLOVIR-RESISTANT CYTOMEGALOVIRUS RETINITIS.
    Tsui JC; Huang V; Kolomeyer AM; Miller CG; Mishkin A; Maguire AM
    Retin Cases Brief Rep; 2024 Mar; 18(2):164-167. PubMed ID: 36730596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review.
    Bright PD; Gompels M; Donati M; Johnston S
    J Clin Virol; 2017 Feb; 87():12-16. PubMed ID: 27987421
    [No Abstract]   [Full Text] [Related]  

  • 12. New Perspectives on Antimicrobial Agents: Maribavir.
    Halpern-Cohen V; Blumberg EA
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0240521. PubMed ID: 35916518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maribavir: Mechanism of action, clinical, and translational science.
    Sun K; Fournier M; Sundberg AK; Song IH
    Clin Transl Sci; 2024 Jan; 17(1):e13696. PubMed ID: 38071422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
    Piret J; Boivin G
    Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.
    Schubert A; Ehlert K; Schuler-Luettmann S; Gentner E; Mertens T; Michel D
    BMC Infect Dis; 2013 Jul; 13():330. PubMed ID: 23870704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.
    Chou S; Song K; Wu J; Bo T; Crumpacker C
    J Infect Dis; 2022 Sep; 226(4):576-584. PubMed ID: 32726419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
    Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
    Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maribavir: First Approval.
    Kang C
    Drugs; 2022 Feb; 82(3):335-340. PubMed ID: 35147913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.
    Chou S; Watters M; Sinha R; Kleiboeker S
    Antiviral Res; 2021 Sep; 193():105139. PubMed ID: 34273445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator-assigned therapy: A US-based study.
    Schultz BG; Bullano M; Paratane D; Rajagopalan K
    Transpl Infect Dis; 2024 Apr; 26(2):e14216. PubMed ID: 38221739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.